Aptinyx Inc (APTX) Receives Average Rating of “Strong Buy” from Analysts

Share on StockTwits

Aptinyx Inc (NASDAQ:APTX) has received a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus price objective of $32.33 for the company and are anticipating that the company will post ($0.48) earnings per share for the current quarter, according to Zacks. Zacks has also given Aptinyx an industry rank of 98 out of 255 based on the ratings given to related companies.

A number of research firms recently commented on APTX. Cowen began coverage on Aptinyx in a research report on Monday, July 16th. They set an “outperform” rating for the company. BMO Capital Markets began coverage on Aptinyx in a research report on Monday, July 16th. They set an “outperform” rating and a $32.00 price objective for the company. Leerink Swann began coverage on Aptinyx in a research report on Monday, July 16th. They set an “outperform” rating and a $35.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on Aptinyx in a research report on Monday, July 16th. They set an “overweight” rating and a $30.00 price objective for the company.

In other Aptinyx news, CEO Norbert G. Riedel bought 2,400 shares of the business’s stock in a transaction that occurred on Monday, June 25th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $38,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Adam Koppel bought 400,000 shares of the business’s stock in a transaction that occurred on Monday, June 25th. The shares were acquired at an average price of $16.00 per share, with a total value of $6,400,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 566,900 shares of company stock valued at $9,070,400.

Several large investors have recently added to or reduced their stakes in APTX. TD Asset Management Inc. purchased a new stake in shares of Aptinyx during the second quarter worth about $253,000. Victory Capital Management Inc. purchased a new stake in shares of Aptinyx during the second quarter worth about $16,984,000. Birchview Capital LP purchased a new stake in shares of Aptinyx during the second quarter worth about $242,000. Dean Capital Investments Management LLC purchased a new stake in shares of Aptinyx during the second quarter worth about $718,000. Finally, NF Trinity Capital Hong Kong Ltd purchased a new stake in shares of Aptinyx during the second quarter worth about $17,121,000. Hedge funds and other institutional investors own 60.05% of the company’s stock.

Shares of NASDAQ:APTX opened at $27.43 on Tuesday. Aptinyx has a 1-year low of $17.35 and a 1-year high of $32.25.

Aptinyx (NASDAQ:APTX) last released its earnings results on Tuesday, August 14th. The company reported ($1.83) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($1.35). The business had revenue of $2.13 million during the quarter, compared to analyst estimates of $2.10 million. equities analysts predict that Aptinyx will post -2.24 earnings per share for the current year.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Further Reading: How can investors find ex-dividend dates?

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply